GC
MRVI icon

Guggenheim Capital’s Maravai LifeSciences MRVI Stock Holding History

Guggenheim Capital’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-11,729
Closed -$97.5K – 1843
2024
Q3 		$97.5K Sell
11,729
-908
-7% -$7.85K ﹤0.01% 1831
2024
Q2 		$90.5K Buy
12,637
+1,364
+12% +$11.8K ﹤0.01% 1832
2024
Q1 		$97.7K Sell
11,273
-189
-2% -$1.28K ﹤0.01% 1847
2023
Q4 		$75.1K Sell
11,462
-447
-4% -$2.89K ﹤0.01% 1858
2023
Q3 		$119K Buy
11,909
+277
+2% +$3.04K ﹤0.01% 1796
2023
Q2 		$145K Sell
11,632
-72
-0.6% -$972 ﹤0.01% 1812
2023
Q1 		$164K Sell
11,704
-106,823
-90% -$1.53M ﹤0.01% 1833
2022
Q4 		$1.7M Buy
+118,527
New +$1.87M 0.01% 917

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Guggenheim Capital's MRVI Position: Q4 2024 in Review

Guggenheim Capital sold out of Maravai LifeSciences (MRVI) in Q4 2024, closing a stake of 11,729 shares — an estimated $97.5K sold.

Guggenheim Capital first reported a position in MRVI in Q4 2022 and held it in 8 quarters. The position peaked at $1.7M in Q4 2022. 185 funds tracked by Wall St. Rank hold MRVI as of Q4 2024.

  • Guggenheim Capital reported no remaining Maravai LifeSciences position as of Q4 2024 after selling out during the quarter.
  • Guggenheim Capital sold 11,729 Maravai LifeSciences shares in Q4 2024, an estimated $97.5K.
  • Guggenheim Capital first reported a position in Maravai LifeSciences in Q4 2022 and held it in 8 quarters.
  • Guggenheim Capital's Maravai LifeSciences position peaked at $1.7M in Q4 2022.
  • 185 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q4 2024.

Based on Guggenheim Capital's 13F filing for Q4 2024, filed 13 Feb 2025.